Compare · GILD vs HUMA
GILD vs HUMA
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Humacyte Inc. (HUMA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and HUMA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $161.19B, about 1046.6x HUMA ($154.0M).
- Over the past year, GILD is up 16.1% and HUMA is down 72.0% - GILD leads by 88.1 points.
- GILD has been more active in the news (5 items in the past 4 weeks vs 1 for HUMA).
- GILD has more recent analyst coverage (25 ratings vs 11 for HUMA).
- Company
- Gilead Sciences Inc.
- Humacyte Inc.
- Price
- $130.18+0.28%
- $0.69-2.16%
- Market cap
- $161.19B
- $154.0M
- 1M return
- +7.20%
- -48.59%
- 1Y return
- +16.10%
- -71.95%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2020
- News (4w)
- 5
- 1
- Recent ratings
- 25
- 11
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
- Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
- Chief Medical Officer Berger Dietmar covered exercise/tax liability with 263 shares and converted options into 533 shares, increasing direct ownership by 1% to 19,252 units (SEC Form 4)
Latest HUMA
- SEC Form SCHEDULE 13G filed by Humacyte Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Humacyte Inc.
- Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
- SEC Form 4 filed by Director Windham-Bannister Susan Richards
- SEC Form 4 filed by Director Constantino Michael T.
- SEC Form 4 filed by Director Wallace Max N.
- SEC Form 4 filed by President, CEO and Director Niklason Laura E
- SEC Form 4 filed by Director Sebelius Kathleen
- SEC Form 4 filed by Director Jones Keith Anthony
- SEC Form 4 filed by Director Green Charles Bruce